罗匹尼罗用于治疗帕金森病。

Ropinirole in the treatment of Parkinson's disease.

作者信息

Zesiewicz T A, Hauser R A

机构信息

Parkinson's Disease and Movement Disorders Center, University of South Florida, 4 Colombia Drive, Suite 410, Tampa, Florida 33606, USA.

出版信息

Expert Opin Investig Drugs. 1999 May;8(5):697-710. doi: 10.1517/13543784.8.5.697.

DOI:10.1517/13543784.8.5.697

PMID:15992124

Abstract

In this review, the pharmacokinetics, safety and tolerability, and clinical efficacy of ropinirole (Requip), a non-ergoline dopamine agonist approved for use in the treatment of Parkinson's disease (PD) are examined. A summary of preclinical and clinical studies is presented. Ropinirole is safe and efficacious as monotherapy in the treatment of early PD and as an adjunct to levodopa in more advanced cases.

摘要

在本综述中，我们研究了罗匹尼罗（Requip）的药代动力学、安全性和耐受性以及临床疗效。罗匹尼罗是一种已被批准用于治疗帕金森病（PD）的非麦角林多巴胺激动剂。文中呈现了临床前和临床研究的总结。罗匹尼罗作为单一疗法治疗早期帕金森病是安全有效的，在更晚期病例中作为左旋多巴的辅助用药也是如此。